<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levothyroxine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levothyroxine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levothyroxine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10807" href="/d/html/10807.html" rel="external">see "Levothyroxine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12550" href="/d/html/12550.html" rel="external">see "Levothyroxine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709010"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Weight reduction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thyroid hormones, including levothyroxine, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F188360"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ermeza;</li>
<li>Euthyrox;</li>
<li>Levoxyl;</li>
<li>Synthroid;</li>
<li>Thyquidity;</li>
<li>Tirosint;</li>
<li>Tirosint-SOL;</li>
<li>Unithroid</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867366"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Eltroxin;</li>
<li>Euthyrox [DSC];</li>
<li>Synthroid</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F188382"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Thyroid Product</li></ul></div>
<div class="block doa drugH1Div" id="F188365"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individual T<sub>4</sub> requirements correlate better with lean body mass than total body weight; in patients with a BMI ≥30 kg/m<sup>2</sup>, initial dosing based on lean body weight is preferred to avoid overreplacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15483074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15483074'])">Ref</a></span>). Initial doses &gt;200 mcg/day are rarely used, regardless of patient weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16087818','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16087818','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Levothyroxine is synthetic thyroxine (T<sub>4</sub>). Due to its prolonged half-life, levothyroxine steady-state concentrations are not achieved until ~6 weeks after therapy is initiated or dosage adjustment; therefore, the full effect at a given dose may not be apparent until then.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38c570b6-3f4a-4617-9a13-c20cd0850cd7">Deceased organ donor management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deceased organ donor management (hormonal resuscitation for the deceased organ donor) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Data supporting benefit are conflicting; if given, guidelines suggest use in hemodynamically unstable donors and/or potential cardiac donors with decreased left ejection fraction (&lt;45%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22511141','lexi-content-ref-25405914','lexi-content-ref-26686437','lexi-content-ref-25978154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22511141','lexi-content-ref-25405914','lexi-content-ref-26686437','lexi-content-ref-25978154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 20 mcg bolus, followed by a continuous infusion of 10 mcg/hour; levothyroxine is usually given as part of combination hormone therapy with vasopressin, methylprednisolone, and insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27275040','lexi-content-ref-25978154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27275040','lexi-content-ref-25978154'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de6dac9f-e2ab-4cab-85d4-6651736f3ce8">Hypothyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypothyroidism: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Dose is individualized according to clinical response and serum thyroid stimulating hormone (TSH) and/or free T<sub>4</sub> concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Ross.5'])">Ref</a></span>). Average maintenance dose is ~1.6 mcg/kg/day; range of required doses is wide and varies from 50 to ≥200 mcg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5'])">Ref</a></span>). Maintenance doses &gt;300 mcg/day are rarely required; in patients who require high doses (eg, &gt;2 mcg/kg/day), consider missed doses, malabsorption, and/or drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Primary hypothyroidism:</i> Note: </b>Adjust initial dose by 12 to 25 mcg/day every 3 to 6 weeks based on clinical response and serum TSH and/or free T<sub>4</sub> concentrations until TSH is normalized at a stable dose for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients</i>
<i> ≤60 years of age without evidence of coronary heart disease: </i>
<b>Oral:</b> Initial: 1.6 mcg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Ross.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients &gt;60 years of age without evidence of coronary heart disease: </i>
<b>Oral:</b> Initial: 25 to 50 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686','lexi-content-ref-25266247','lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686','lexi-content-ref-25266247','lexi-content-ref-Ross.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with coronary heart disease:</i>
<b>Oral:</b> Initial: 12.5 to 50 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686','lexi-content-ref-25266247','lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686','lexi-content-ref-25266247','lexi-content-ref-Ross.5'])">Ref</a></span>); monitor for the onset of cardiac symptoms (eg, angina) and decrease the dose if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686'])">Ref</a></span>). <b>Note:</b> Patients without other significant comorbidities who have had recent successful interventions to treat ischemia (eg, coronary artery bypass grafting or coronary artery stenting) can initially receive up to 80% of the weight-based dose (1.6 mcg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5'])">Ref</a></span>). See also “Dosing” at the top of “Dosing: Adult” section.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pregnant patients: </i>
<b>Note: </b>Thyroid function tests should be interpreted using population-based, trimester-specific reference ranges for TSH and assay method- and trimester-specific reference ranges for serum free T<sub>4</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Preexisting hypothyroidism in patients receiving levothyroxine prenatally: Patients with suspected or confirmed pregnancy:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> Immediately increase the current dose by ~20% to 30% (eg, administer 2 additional tablets weekly) and adjust dose as needed every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Newly diagnosed overt hypothyroidism:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral: </b>Initial: 1.6 mcg/kg/day; a lower dose of 1 mcg/kg/day may be used in some patients. Adjust dose by 12.5 to 25 mcg/day every 4 to 6 weeks if needed based on TSH levels to restore euthyroidism as soon as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443080','lexi-content-ref-28056690','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443080','lexi-content-ref-28056690','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Newly diagnosed subclinical hypothyroidism (off-label use):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> The decision to treat is based on the degree of TSH elevation and the presence or absence of thyroid peroxidase antibodies. If treated, goal is to restore euthyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>). Some experts treat pregnant patients with subclinical hypothyroidism (defined as TSH above trimester-specific normal reference range [or &gt;4 milliunits/L if trimester-specific range unavailable] with normal free T<sub>4</sub>), regardless of thyroid peroxidase antibody status, and would consider treatment in select pregnant patients with TSH levels between 2.6 and 4 milliunits/L based on the presence or absence of thyroid peroxidase antibodies, clinical factors, and patient preferences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> Initial: 1 mcg/kg/day <b>or</b> 25 to 50 mcg daily; adjust dose by ~12.5 to 25 mcg/day as needed every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690','lexi-content-ref-31598570','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690','lexi-content-ref-31598570','lexi-content-ref-Manu.1'])">Ref</a></span>). Therapy should be closely monitored and adjusted to avoid overtreatment, which may result in adverse maternal and fetal outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32975922','lexi-content-ref-Ross.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32975922','lexi-content-ref-Ross.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Postpartum dosage adjustment: In patients treated prenatally for hypothyroidism, decrease the dose to preconception levels following delivery. In patients who were initiated on levothyroxine during pregnancy, evaluate the need for continued treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Subclinical hypothyroidism (off-label use): </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Treatment may be considered in select patients with TSH levels above normal reference range depending on degree of TSH abnormality, age, and symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30285179','lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30285179','lexi-content-ref-Ross.4'])">Ref</a></span>). In patients with TSH &gt;10 milliunits/L, treatment is generally warranted, whereas benefit of treatment in asymptomatic patients with TSH levels between 4.5 and 10 milliunits/L is not well established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686','lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686','lexi-content-ref-Ross.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults &lt;50 years of age without coronary heart disease: <b>Oral:</b> Initial: 1.5 mcg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24783053','lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24783053','lexi-content-ref-Ross.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients with coronary heart disease or ≥50 years of age: <b>Oral:</b> Initial: 25 to 50 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24783053','lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24783053','lexi-content-ref-Ross.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Dosage adjustment: Initial dose is adjusted by 12 to 25 mcg/day once every 6 weeks until targeted TSH is achieved with a stable dose for ≥6 weeks; thereafter assess TSH level annually (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Postpartum thyroiditis (hypothyroid phase): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in patients who are symptomatic, breastfeeding, or planning another pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690'])">Ref</a></span>); some experts will treat asymptomatic patients who have a TSH ≥10 milliunits/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burman.1'])">Ref</a></span>). Dosing recommendations and duration of treatment are not standardized; treatment is individualized according to clinical assessment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> An initial dose of 50 to 100 mcg once daily <b>or </b>1.6 mcg/kg/day has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burman.1','lexi-content-ref-30844908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burman.1','lexi-content-ref-30844908'])">Ref</a></span>). Adjust dose every 6 weeks if needed based on TSH levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Duration of therapy:</b> After 6 to 12 months, may consider gradual tapering of the dose (eg, every 6 to 8 weeks) with a goal of discontinuation; levothyroxine should not be tapered in patients who are pregnant or attempting to conceive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28056690','lexi-content-ref-Burman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28056690','lexi-content-ref-Burman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Secondary or tertiary (central) hypothyroidism: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Patients with secondary or tertiary (central) hypothyroidism should undergo assessment of their pituitary-adrenal function prior to initiation of therapy. If shown to have adrenal insufficiency, concomitant administration of a glucocorticoid is recommended to prevent an adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 1.6 mcg/kg/day; initiate treatment at a lower dose in older patients or patients with underlying coronary heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Adjust dose based on clinical response and serum free T<sub>4</sub> concentrations. TSH <b>cannot</b> be used to monitor therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Ross.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hypothy</i></b>
<b>
<i>roidism, immune checkpoint inhibitor-induced: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Healthy adults ≤65 years of age: <b>Oral:</b> Initial: 1.5 to 1.6 mcg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults with coronary heart disease or &gt;65 years of age: <b>Oral:</b> Initial: 25 to 50 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5b8f1da-9bd4-4501-b49d-55160296d783">Myxedema coma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myxedema coma: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial loading dose of 200 to 400 mcg as a slow bolus; followed by a daily replacement dose of 50 to 100 mcg until the patient improves clinically and can transition to oral therapy; consider doses on the lower end of the dosing range for smaller or older patients and those with a history of or at risk for coronary disease or arrhythmia; concomitant glucocorticoid therapy (eg, stress doses of hydrocortisone) is required until the possibility of coexisting adrenal insufficiency is excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Ross.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Ross.3'])">Ref</a></span>); some experts administer liothyronine (T<sub>3</sub>) concomitantly with levothyroxine (T<sub>4</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a568fe5a-d659-497e-bb08-59f0bb6fceec">TSH suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>TSH suppression: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Well-differentiated thyroid cancer (papillary and follicular):</i> Dosage is highly individualized as the degree of TSH suppression is initially based on the risk of disease recurrence using a staging system such as the American Thyroid Association (ATA) risk-of-recurrence stratification system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26462967','lexi-content-ref-Tuttle.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26462967','lexi-content-ref-Tuttle.1'])">Ref</a></span>). Long-term TSH suppression goals should account for response to therapy, risk of recurrent disease, age, and comorbid conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26462967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26462967'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 1.6 to 2 mcg/kg/day immediately postsurgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tuttle.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tuttle.1'])">Ref</a></span>); adjust dose as needed in 6 weeks based on TSH suppression goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26462967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26462967'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>For patients with ATA low- and intermediate-risk disease whose initial surgery was a lobectomy, some experts initiate therapy at a later time when TSH concentrations or disease status dictate a need (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26462967','lexi-content-ref-25088372','lexi-content-ref-Tuttle.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26462967','lexi-content-ref-25088372','lexi-content-ref-Tuttle.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Benign solitary nodules and nontoxic multinodular goiter:</i> Routine use of levothyroxine for TSH suppression is not recommended in euthyroid patients with benign thyroid nodules in iodine-sufficient geographic areas. In patients deemed appropriate candidates, treatment should never be fully suppressive (ie, do not target TSH &lt;0.1 milliunits/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27167915','lexi-content-ref-26462967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27167915','lexi-content-ref-26462967'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV/IM replacement in patients who are temporarily unable to receive oral therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (off-label route), IV (off-label use):</b> Administer ~70% to 80% of the established oral dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-Manzullo.1','lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-Manzullo.1','lexi-content-ref-Ross.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dose conversion from other thyroid hormone products to levothyroxine:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When switching from other thyroid hormone products to levothyroxine, monitor TSH levels 6 weeks after levothyroxine is initiated and adjust accordingly to maintain TSH levels in the target range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from desiccated thyroid to levothyroxine:</i>
<b>Oral: </b>60 or 65 mg/day of desiccated thyroid is equivalent to ~88 to 100 mcg/day of levothyroxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23539727','lexi-content-ref-34185829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23539727','lexi-content-ref-34185829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from levothyroxine/liothyronine combinations to levothyroxine:</i>
<b>Oral:</b> Liothyronine is ~4 times as potent as levothyroxine. Therefore, one approach is to multiply the liothyronine component by 4 and add this to the current levothyroxine component to get the new daily levothyroxine dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ross.5','lexi-content-ref-Thyrolar.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ross.5','lexi-content-ref-Thyrolar.1'])">Ref</a></span>). For example, if the current dose is liothyronine 12.5 mcg/levothyroxine 50 mcg per day, the new levothyroxine dose would be calculated as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">New levothyroxine dose (mcg/day) = (4 × 12.5 mcg/day [current liothyronine dose]) + 50 mcg/day [current levothyroxine dose] = 100 mcg/day</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991315"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576928'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576928'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988657"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F53092989"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">Individual T<sub>4</sub> requirements correlate better with lean body weight than total body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15483074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15483074'])">Ref</a></span>); weight-based dosing may overestimate initial replacement doses in patients with obesity; as such, dosing in obesity must be individualized.</p></div>
<div class="block dot drugH1Div" id="F24825220"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Cardiac symptoms (onset or worsening): Manufacturer labeling recommends reducing dosage or withholding therapy for 7 days and then resuming therapy at reduced dosage. Specific dosing recommendations are not provided.</p></div>
<div class="block doe drugH1Div" id="F188366"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F188377"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12550" href="/d/html/12550.html" rel="external">see "Levothyroxine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Oral solution is available in multiple concentrations; dosing should be presented in mcg of levothyroxine; use extra precaution when verifying product formulation and calculation of dose volumes.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76311ecb-7f7b-444e-9d48-e5c07c993661">Hypothyroidism, acquired or congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypothyroidism, acquired or congenital: Note:</b> Hyperactivity in older children may be minimized by starting at one-quarter (25%) of the recommended dose and increasing each week by that amount until the full dose is achieved (4 weeks).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: <b>Note:</b> Doses should be adjusted based on clinical response and laboratory parameters. Brand name tablets are preferred over generic tablets for treating congenital hypothyroidism. Switching between different levothyroxine products and/or formulations may result in variations in the administered dose, alter thyroid-stimulating hormone (TSH) values, and is generally not recommended; if products or formulations are changed, close monitoring of TSH is recommended; patients with congenital hypothyroidism may be more sensitive to changes in formulations. Commercially available oral liquids may have a higher bioavailability than tablets; neonates and infants receiving commercially available oral liquids may need more frequent monitoring. Experts recommend against the use of extemporaneously prepared solutions/suspensions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-23264396','lexi-content-ref-23312689','lexi-content-ref-33272083','lexi-content-ref-24247169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-23264396','lexi-content-ref-23312689','lexi-content-ref-33272083','lexi-content-ref-24247169'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 3 months: Oral: 10 to 15 mcg/kg/dose once daily; in severe cases of congenital hypothyroidism (serum T<sub>4</sub> &lt;5 mcg/dL), initiating at higher doses (12 to 17 mcg/kg/dose) may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-33272083','lexi-content-ref-12461494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-33272083','lexi-content-ref-12461494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;3 to 6 months: Oral: 8 to 10 mcg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;6 to 12 months: Oral: 6 to 8 mcg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 5 years: Oral: 5 to 6 mcg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 12 years: Oral: 4 to 5 mcg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;12 years with incomplete growth and puberty: Oral: 2 to 3 mcg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents with growth and puberty complete: Oral: 1.6 mcg/kg/dose once daily; adjust dose by 12.5 to 25 mcg/day every 4 to 6 weeks as needed. Usual doses are ≤200 mcg/day (range: 100 to 125 mcg/day [70 kg adult]); doses ≥300 mcg/day are rare (consider poor compliance, malabsorption, and/or drug interactions).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cardiac disease:</i>
<b>Note: </b>Lower initial doses are recommended.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: Initial: ~50% of target replacement dose; increase after 2 weeks based on free thyroxine levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33272083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33272083'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents with growth and puberty complete: Oral: Initial: 12.5 to 25 mcg/day; adjust dose by 12.5 to 25 mcg increments at 6- to 8-week intervals as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: <b>Note: </b>The relative bioavailability of injectable and oral levothyroxine has not been established; use caution when switching patients from oral to IV as accurate dosing conversions have not been established.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: Initial: ~75% to 80% of the oral dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-33272083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-33272083'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="641e1a1c-d3fa-4ba8-bdf5-3ae9b2b2265b">Thyroid-stimulating hormone suppression in well differentiated thyroid cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid-stimulating hormone suppression in well differentiated thyroid cancer (papillary):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Highly individualized; doses &gt;2 mcg/kg/day may be needed to suppress TSH to &lt;0.1 milliunits/L in high-risk tumors; for intermediate-risk tumors, initial TSH suppression to 0.1 to 0.5 milliunits/L is recommended; for low-risk tumors, TSH may be maintained at 0.5 to 1 milliunits/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25900731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25900731'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38c570b6-3f4a-4617-9a13-c20cd0850cd7">Deceased organ donor management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deceased organ donor management (hormonal resuscitation for the deceased organ donor) </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nakagawa.1','lexi-content-ref-15640648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nakagawa.1','lexi-content-ref-15640648'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: IV: Initial: 5 mcg/kg bolus dose, followed by 1.4 mcg/kg/<b>hour</b> infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 to 12 months: IV: Initial: 4 mcg/kg bolus dose, followed by 1.3 mcg/kg/<b>hour</b> infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: IV: Initial: 3 mcg/kg bolus dose, followed by 1.2 mcg/kg/<b>hour</b> infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: IV: Initial: 2.5 mcg/kg bolus dose, followed by 1 mcg/kg/<b>hour</b> infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤16 years: IV: Initial: 1.5 mcg/kg bolus dose, followed by 0.8 mcg/kg/<b>hour</b> infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;16 years: IV: Initial: 0.8 mcg/kg bolus dose, followed by 0.8 mcg/kg/<b>hour</b> infusion.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117788"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51117789"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55501547"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially life-threatening cardiovascular effects may occur with levothyroxine. The effects commonly result from overtreatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17923583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17923583'])">Ref</a></span>) but can also occur with initiation of levothyroxine, especially in patients with severe hypothyroidism or in patients with a history of cardiovascular disease or arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13752096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13752096'])">Ref</a></span>). Effects may include <b>palpitations</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11134131','lexi-content-ref-1391296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11134131','lexi-content-ref-1391296'])">Ref</a></span>), <b>tachycardia</b>, exercise intolerance, <b>dyspnea</b> on exertion, widened pulse pressure, and atrial fibrillation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17923583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17923583'])">Ref</a></span>); cardiac overload and arrhythmias have been described in infants.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; several proposed mechanisms, including abnormal myocardial response to catecholamines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19686084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19686084'])">Ref</a></span>) and increased number and sensitivity of adrenergic receptors in the cardiovascular system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081673'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13752096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13752096'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Overtreatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17923583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17923583'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (conflicting data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13752096','lexi-content-ref-17923583','lexi-content-ref-28402245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13752096','lexi-content-ref-17923583','lexi-content-ref-28402245'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F188321"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are primarily those of hyperthyroidism due to therapeutic overdosage.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac failure, flushing, increased blood pressure, increased pulse, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Goiter (exophthalmic; IV), menstrual disease, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, diarrhea, increased appetite, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Reduced fertility</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, emotional lability, fatigue, headache, heat intolerance, hyperactive behavior, idiopathic intracranial hypertension (children), insomnia, irritability, myasthenia, nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Craniosynostosis (infants; dose-related [ie, overtreatment]) (Penfold 1975), decreased bone mineral density (dose- and duration-related) (Coindre 1986; Schneider 1994), muscle spasm, slipped capital femoral epiphysis (children), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Oe 2007), cardiomyopathy (takotsubo) (Balsa 2017), palpitations (Biondi 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Lichenoid eruption (Kaur 2003), urticaria (Sala 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (Syed 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Hlaihel 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Acute mania (Yu 2017), seizure</p></div>
<div class="block coi drugH1Div" id="F188337"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Uncorrected adrenal insufficiency; consider contraindications for oral therapy if using as a temporary substitute for oral treatment (off-label use) in patients with chronic hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Uncorrected adrenal insufficiency; hypersensitivity to glycerol (Ermeza, Tirosint-SOL oral solution) and edetate disodium (Ermeza); <b>Note:</b> Consult individual product labeling as they may vary. Reported hypersensitivity to levothyroxine or any component of the formulation is not considered an absolute contraindication (ATA [Jonklaas 2014]); refer to "Warnings/Precautions."</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to levothyroxine or any component of the formulation; untreated pituitary insufficiency, subclinical thyrotoxicosis, overt thyrotoxicosis of any etiology, acute myocardial infarction, acute myocarditis, or acute pancarditis; pregnant women taking medications for hyperthyroidism (eg, methimazole, propylthiouracil). <b>Note:</b> Consult individual product labeling as they may vary.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F188318"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede levothyroxine therapy in patients with adrenal insufficiency. Use is contraindicated in patients with uncorrected adrenal insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benign thyroid nodules: Appropriate use: Routine use of T<sub>4</sub> for thyroid stimulating hormone (TSH) suppression is not recommended in patients with benign thyroid nodules. Treatment should never be fully suppressive (TSH &lt;0.1 milliunits/L) (AACE/ACE/AME [Gharib 2016]; ATA [Haugen 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">- Use of T<sub>4</sub> may be considered in association with iodine supplementation only in young patients residing in iodine-deficient areas with small thyroid nodules and no evidence of functional autonomy (AACE/ACE/AME [Gharib 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">- Use should be avoided in postmenopausal patients, older adults, patients with cardiovascular disease, osteoporosis, large thyroid nodules or long-standing goiters, or low-normal TSH levels (AACE/ACE/AME [Gharib 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: May require lower initial dose and conservative dose titration. Refer to dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus (may worsen glycemic control) and diabetes insipidus (thyroid hormone increases glomerular filtration rate and downregulates aquaporin channels in the renal tubules, which could affect urinary output) (Mariani 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Thyroid hormone overreplacement may result in increased bone resorption and decreased bone mineral density, especially in postmenopausal patients; use the lowest effective dose to achieve therapy goals.</p>
<p style="text-indent:-2em;margin-left:4em;">• Subacute thyroiditis: Transient and mild hypothyroidism during the recovery phase of subacute thyroiditis often can be managed without treatment; levothyroxine therapy may be required in patients with overt and clinical hypothyroidism (Farwell 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution; May require lower initial dose and conservative dose titration. Refer to dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Switching between different levothyroxine products may result in variations in the administered dose and altered TSH values and is not generally recommended; if formulations are changed, close monitoring of TSH is recommended (ATA [Jonklaas 2014]). Pediatric patients with congenital hypothyroidism may be more sensitive to changes in formulation (Carswell 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Patients with reported hypersensitivity to levothyroxine may be managed with dose reductions and slow titration, by switching formulations or products, or referral to an allergist (ATA [Jonklaas 2014]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878518"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. In neonates and infants, aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain glycerol; glycerol may cause GI irritation and lead to vomiting and/or osmotic diarrhea. Pediatric patients ≤3 months of age are especially susceptible to fluid and electrolyte disturbances from glycerol-induced GI irritation; closely monitor these patients for signs and symptoms.</p></div>
<div class="block foc drugH1Div" id="F188330"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tirosint: 13 mcg, 25 mcg, 37.5 mcg, 44 mcg, 50 mcg, 62.5 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/5 mL (5 mL); 200 mcg/5 mL (5 mL); 500 mcg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tirosint-SOL: 37.5 mcg/mL (1 mL); 44 mcg/mL (1 mL); 62.5 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ermeza: 150 mcg/5 mL (75 mL, 150 mL) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thyquidity: 100 mcg/5 mL (100 mL) [contains methylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tirosint-SOL: 13 mcg/mL (1 mL); 25 mcg/mL (1 mL); 50 mcg/mL (1 mL); 75 mcg/mL (1 mL); 88 mcg/mL (1 mL); 100 mcg/mL (1 mL); 112 mcg/mL (1 mL); 125 mcg/mL (1 mL); 137 mcg/mL (1 mL); 150 mcg/mL (1 mL); 175 mcg/mL (1 mL); 200 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg (1 ea); 200 mcg (1 ea); 500 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 25 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 25 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 50 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 50 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 75 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 75 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 88 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 88 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 100 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 100 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 112 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 112 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 125 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 125 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 137 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 137 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 150 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 150 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 175 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 175 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 200 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 200 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 25 mcg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 50 mcg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 75 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 88 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 100 mcg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 112 mcg [scored; contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 125 mcg [scored; contains fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 137 mcg, 150 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 175 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levoxyl: 200 mcg [scored; contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 25 mcg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 50 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 75 mcg [scored; contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 88 mcg [scored; contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 100 mcg [scored; contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 112 mcg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 125 mcg [scored; contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 137 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 150 mcg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 175 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 200 mcg [scored; contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 300 mcg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 25 mcg [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 50 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 75 mcg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 88 mcg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 100 mcg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 112 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 125 mcg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 137 mcg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 150 mcg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 175 mcg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 200 mcg [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Unithroid: 300 mcg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg</p></div>
<div class="block geq drugH1Div" id="F188314"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F188340"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Levothyroxine Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $4.95 - $5.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tirosint Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">44 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $5.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ermeza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg/5 mL (per mL): $2.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Levothyroxine Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/5 mL (per mL): $17.98 - $26.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/mL (per mL): $89.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/5 mL (per mL): $53.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg/5 mL (per mL): $133.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Thyquidity Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/5 mL (per mL): $1.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tirosint-SOL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">44 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/mL (per mL): $5.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Levothyroxine Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $110.17 - $126.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $253.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg (per each): $633.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Euthyrox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $0.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $0.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $0.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $0.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $0.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $0.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $0.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $1.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $1.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Levo-T Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $0.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $0.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $0.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $0.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $0.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $0.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $0.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $0.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $0.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg (per each): $1.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Levothyroxine Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $0.13 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $0.19 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $0.09 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $0.10 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $0.13 - $1.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg (per each): $0.13 - $1.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Levoxyl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $0.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $1.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $1.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $1.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $1.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $1.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $1.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $1.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Synthroid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Unithroid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg (per each): $4.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg (per each): $4.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $4.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">88 mcg (per each): $4.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $4.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112 mcg (per each): $4.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $4.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">137 mcg (per each): $4.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mcg (per each): $4.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg (per each): $4.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $4.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mcg (per each): $4.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867367"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg/5 mL (5 mL); 500 mcg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 500 mcg (1 ea, 10 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg (1 ea); 500 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 25 mcg [DSC] [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 50 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 75 mcg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 88 mcg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #5 (tartrazine)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 100 mcg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 112 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 125 mcg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #5 (tartrazine)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 137 mcg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 150 mcg [DSC], 175 mcg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 200 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Euthyrox: 300 mcg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 25 mcg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 50 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 75 mcg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 88 mcg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 100 mcg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 112 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 125 mcg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 137 mcg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 150 mcg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 175 mcg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 200 mcg [contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synthroid: 300 mcg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg, 100 mcg, 150 mcg, 200 mcg</p></div>
<div class="block adm drugH1Div" id="F188334"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer consistently in the morning on an empty stomach, at least 30 to 60 minutes or 15 minutes (Tirosint-SOL) before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686','lexi-content-ref-25266247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686','lexi-content-ref-25266247'])">Ref</a></span>). Do not administer within 4 hours of calcium- or iron-containing products or bile acid sequestrants.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Must be swallowed whole; do not cut, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Ermeza:</i> Administer directly into mouth using the 5 mL or 10 mL oral syringe (provided in carton); do not use a household teaspoon or tablespoon. For doses ≤5 mL, use the 5 mL syringe and round up or down to the nearest graduation mark (0.1 mL) and for doses &gt;5 mL, use the 10 mL syringe and round up or down to the nearest graduation mark (0.2 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thyquidity: </i>Administer directly into mouth using a calibrated oral syringe; do not use a household teaspoon or tablespoon.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tirosint-SOL:</i> May administer undiluted or diluted in water only (do not dilute with any other liquid); if administering undiluted, squeeze contents of single unit-dose ampule into mouth or onto a spoon and administer immediately. If diluting with water, squeeze contents of ampule into a glass or cup, stir, and then administer entire contents immediately. Rinse glass or cup with additional water and administer contents to ensure entire dose is consumed.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Administer with a full glass of water (choking, gagging, and dysphagia have been reported with some formulations). May be crushed and suspended in 5 to 10 mL of water; suspension should be used immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric tube: Bioavailability of extemporaneously prepared levothyroxine (crushed tablets suspended in water) may be reduced if administered with enteral tube feeds; although data are limited, temporarily holding tube feeds before and after levothyroxine administration (eg, for 30 to 60 minutes) has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23246686','lexi-content-ref-21139130','lexi-content-ref-24789541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23246686','lexi-content-ref-21139130','lexi-content-ref-24789541'])">Ref</a></span>). Alternatively, use of the oral solution (Tirosint-SOL) may not require interruption of tube feeds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24789541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24789541'])">Ref</a></span>). Consider more frequent thyroid function test monitoring (eg, every 1 to 3 weeks) if prolonged administration of enteral tube feeds is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21139130','lexi-content-ref-24789541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21139130','lexi-content-ref-24789541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered by IV injection at a maximum rate of 100 mcg/minute; may also be administered IM when oral administration is not feasible (off-label route).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</i> After IV bolus administration, may administer as a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17488392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17488392'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613150"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer consistently on an empty stomach at the same time each day, either 30 to 60 minutes prior to breakfast <b>or</b> at night 3 to 4 hours after the last meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247'])">Ref</a></span>); allow families to choose morning or bedtime regimen based on convenience as efficacy is comparable between regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30312169','lexi-content-ref-Radhakrishnan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30312169','lexi-content-ref-Radhakrishnan.1'])">Ref</a></span>). If administration on an empty stomach poses a challenge, particularly in neonates, infants, and small children, it may be administered with food (avoiding soy protein and vegetable fiber) to improve adherence and consistency of administration; consistent administration in relation to time of day and to food is most important (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33272083','lexi-content-ref-20547262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33272083','lexi-content-ref-20547262'])">Ref</a></span>). Do not administer within 4 hours of other medications known to interfere with levothyroxine absorption (eg, calcium- or iron-containing products or bile acid sequestrants).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Children ≥6 years and Adolescents: Must be swallowed whole; do not cut, crush, chew, or attempt to dissolve capsules in water to prepare a suspension.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Thyquidity: </i>Administer directly into mouth using a calibrated oral syringe; do not use a household teaspoon or tablespoon.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tirosint-SOL:</i> May administer undiluted or diluted in water only (do not dilute with any other liquid).</p>
<p style="text-indent:-2em;margin-left:8em;">Undiluted: Squeeze contents of single unit-dose ampule into mouth or onto a spoon and administer immediately.</p>
<p style="text-indent:-2em;margin-left:8em;">Dilution with water: Squeeze contents of ampule into a glass or cup containing water, stir, and then administer entire contents immediately. Rinse glass or cup with additional water and administer contents to ensure entire dose is consumed.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer with a full glass of water (choking, gagging, and dysphagia has been reported with some formulations). For infants and children who cannot swallow tablet whole, crush tablet and mix with small amount (5 to 10 mL) of water, breast milk, or non–soy-based formula and use immediately (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-33272083','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16740880','lexi-content-ref-25266247','lexi-content-ref-33272083','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric tube: Bioavailability of levothyroxine (crushed tablets suspended in water) is reduced if administered with enteral tube feeds. Since holding feedings may not be appropriate for some patients and holding feedings for at least 1 hour before and after levothyroxine administration may not completely resolve the interaction, an increase in dose (eg, additional 25 mcg in adults) may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21139130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21139130'])">Ref</a></span>). Consider more frequent thyroid function test monitoring (eg, every 1 to 3 weeks) if prolonged administration of enteral tube feeds is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21139130','lexi-content-ref-24789541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21139130','lexi-content-ref-24789541'])">Ref</a></span>). Adult data suggest that use of the oral solution (Tirosint-SOL) may not require interruption of tube feeds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24789541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24789541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypothyroidism, acquired or congenital: </i>Administer IV over 2 to 3 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Deceased organ donor management</i>: IV bolus, followed by continuous IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nakagawa.1','lexi-content-ref-15640648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nakagawa.1','lexi-content-ref-15640648'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: May be administered intramuscularly when oral administration is not feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FreseniusKabi.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FreseniusKabi.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>Given the long half-life of levothyroxine, patients should be advised to take any missed doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F188333"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hypothyroidism: Replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology. Specific indications include primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism; secondary and tertiary hypothyroidism are also referred to as “central” hypothyroidism. <b>Note:</b> Levothyroxine monotherapy is recommended as the preferred thyroid preparation for the treatment of hypothyroidism (ATA [Jonklaas 2014]; ES [Fleseriu 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Pituitary thyrotropin-stimulating hormone suppression: An adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injectable:</b> Treatment of myxedema coma</p></div>
<div class="block off-label drugH1Div" id="F25726760"><span class="drugH1">Use: Off-Label: Adult</span><p>Deceased organ donor management (hormonal resuscitation for the deceased organ donor); Subclinical hypothyroidism</p></div>
<div class="block mst drugH1Div" id="F188391"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Levothyroxine may be confused with lamoTRIgine, Lanoxin, levoFLOXacin, liothyronine</p>
<p style="text-indent:-2em;margin-left:4em;">Levoxyl may be confused with Lanoxin, Levaquin, Luvox</p>
<p style="text-indent:-2em;margin-left:4em;">Synthroid may be confused with Symmetrel</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oral solutions vary in concentration; consider total dosage in terms of mcg and not volume (mL) when converting between oral solution products.</p>
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">To avoid errors due to misinterpretation of a decimal point, always express dosage in mcg (<b>not</b> mg).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299600"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F188323"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 hours prior to or one hour after bile acid sequestrants, or monitor for decreased serum concentrations and clinical effects of oral thyroid products during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to calcium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Thyroid Products may decrease the serum concentration of Cardiac Glycosides. Specifically, returning to a euthyroid state from a hypothyroid state may decrease the serum concentration of cardiac glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofenamate: May decrease the protein binding of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May decrease the protein binding of Thyroid Products. This may lead to a transient increase in free thyroid hormone concentrations and to a later decrease in total thyroid hormone concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May decrease the serum concentration of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: May decrease the serum concentration of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron preparations or levothyroxine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Levothyroxine may enhance the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: Levothyroxine may enhance the hypertensive effect of Ketamine. Levothyroxine may enhance the tachycardic effect of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Separate the administration of thyroid products and lanthanum by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: Levothyroxine may enhance the adverse/toxic effect of Maprotiline. Maprotiline may enhance the adverse/toxic effect of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meclofenamate: May decrease the protein binding of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefenamic Acid: May decrease the protein binding of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if a multivitamin is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and orlistat  by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of Levothyroxine. Management: Administer oral levothyroxine at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polaprezinc: May decrease the serum concentration of Levothyroxine. Management: Separate administration of polaprezinc and levothyroxine by at least several hours, and monitor for reduced effects of levothyroxine during polaprezinc treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: May decrease the absorption of Levothyroxine. Management: Consider separating doses of raloxifene and levothyroxine by several hours. Monitor for reduced effects of levothyroxine and reduced serum concentrations of thyroxine if raloxifene and levothyroxine are used concomitantly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide: May increase the serum concentration of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer: May decrease the serum concentration of Levothyroxine. Management: Separate administration of sevelamer and levothyroxine by at least 4 hours to decrease the risk of a significant interaction. Monitor clinical and laboratory response to levothyroxine closely when used together with sevelamer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue thyroid products before sodium iodide I-131 administration, and avoid concurrent use. Stop triiodothyronine (T3) 2 weeks before, and stop thyroxine (T4) 4 weeks before, sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to sodium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatropin: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Soybean: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucroferric Oxyhydroxide: May decrease the serum concentration of Levothyroxine. Management: Administer oral/enteral levothyroxine at least 4 hours before administration of sucroferric oxyhydroxide. No interaction is anticipated with parenteral levothyroxine administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: Levothyroxine may enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolfenamic Acid: May decrease the protein binding of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F188355"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula), soy, grapefruit juice, espresso coffee, cottonseed meal, walnuts, calcium, iron, and dietary fiber may interfere with absorption of levothyroxine from the GI tract. Management: Take in the morning on an empty stomach at least 30 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Garber 2012]; ATA [Jonklaas 2014]). Consider an increase in dose if taken with enteral tube feed. Do not administer within 4 hours of calcium- or iron-containing products.</p></div>
<div class="block rep_considerations drugH1Div" id="F52942443"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Overt hypothyroidism increases the risk of irregular menses and infertility; treatment with levothyroxine is recommended to normalize thyroid function in infertile patients with overt hypothyroidism who desire to become pregnant. Levothyroxine may also be used in infertile patients with subclinical hypothyroidism using assisted reproductive techniques to become pregnant (ATA [Alexander 2017]; ETA [Poppe 2021]).</p></div>
<div class="block pri drugH1Div" id="F188341"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Levothyroxine has not been shown to increase the risk of congenital abnormalities or miscarriage; however, normal levels of maternal thyroid hormones are required for fetal development. Untreated maternal hypothyroidism can be associated with adverse effects in both the mother and fetus, including spontaneous abortion, stillbirth, premature birth, low birth weight, impaired neurocognitive development in the offspring, abruptio placentae, gestational hypertension, and preeclampsia (ACOG 2020; ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Thyroid replacement therapy minimizes the risk of adverse pregnancy outcomes in patients with overt hypothyroidism and treatment is recommended for all patients with overt hypothyroidism during pregnancy (ACOG 2020; ATA [Alexander 2017]). Treatment may also improve some pregnancy outcomes in patients with subclinical hypothyroidism (ACOG 2020; Andersen 2020; Bein 2021). Treatment for subclinical hypothyroidism is not recommended for patients with negative thyroid peroxidase antibody status when thyroid-stimulating hormone (TSH) is in the normal pregnancy specific range (or &lt;4 milliunits/L if trimester-specific range unavailable) (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Levothyroxine is the preferred treatment of maternal hypothyroidism; other agents should not be used during pregnancy. Due to alterations of endogenous maternal thyroid hormones, hypothyroid patients treated with levothyroxine prior to pregnancy require a dose increase as soon as pregnancy is confirmed (ACOG 2020; ATA [Alexander 2017]). Close monitoring of pregnant patients is recommended (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients in the hypothyroid phase of postpartum thyroiditis (who do not have Graves’) may also require levothyroxine treatment. This includes patients who are symptomatic, breastfeeding, planning another pregnancy, or have a TSH greater than the reference range. Dosing recommendations and duration of treatment are not standardized; treatment is individualized according to clinical assessment. Tapering of the dose with a goal of discontinuation, if possible, may begin after 6 to 12 months of treatment; the dose should be gradually decreased with TSH monitoring every 6 to 8 weeks (ATA [Alexander 2017]; Stagnaro-Green 2012).</p></div>
<div class="block brc drugH1Div" id="F188342"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">As part of a prospective cohort study of breastfeeding mothers, 5 mother-infant pairs reported levothyroxine exposure (dose, duration, relationship to breastfeeding not provided). There were no reports of adverse reactions, including diarrhea, drowsiness, irritability, or poor feeding (Ito 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Adequate thyroid hormone concentrations are required to maintain normal lactation. Patients with overt hypothyroidism or subclinical hypothyroidism experiencing poor lactation and who wish to breastfeed should be treated (ATA [Alexander 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. The World Health Organization considers levothyroxine to be compatible with breastfeeding (WHO 2002). When thyroid replacement therapy is needed in breastfeeding patients, use of levothyroxine is preferred (ATA [Alexander 2017]).</p></div>
<div class="block mop drugH1Div" id="F188328"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pediatrics:</b> Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation and accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor thyroid-stimulating hormone (TSH) and total or free T<sub>4</sub> at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adults:</b> Heart rate, BP, new/worsened cardiac symptoms (eg, chest pain, palpitations, edema), clinical signs of hypo- and hyperthyroidism; bone mineral density (particularly with long-term use in postmenopausal patients).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary hypothyroidism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Dosage adjustment phase: In patients who experience symptomatic improvement following initiation of therapy or dosage adjustment, measure TSH response at 6 weeks and adjust therapy as needed (ATA [Jonklaas 2014]). In those who continue to experience symptoms, consider measuring free T<sub>4</sub> (FT<sub>4</sub>) and TSH at 3 weeks and increasing the dose if FT<sub>4</sub> is below normal (Ross 2022a); the full effect of the dose may not be apparent at 3 weeks as levothyroxine does not achieve steady state until ~6 weeks post-initiation or dosage adjustment. Continue to measure serum TSH (and FT<sub>4</sub> if levothyroxine steady state has not yet been achieved) every 3 to 6 weeks and adjust the dose until the TSH level is within the goal range (ATA [Jonklaas 2014]; Ross 2022e).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance phase: Once TSH levels are at goal, may recheck levels at 4 to 6 months and then annually if they remain within the goal range; if the levothyroxine dose is adjusted or if the formulation is changed, resume monitoring as instructed in the “Dosage adjustment phase” section above (ATA [Jonklaas 2014]; Ross 2022a).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypothyroidism in pregnant patients:</i> Thyroid function tests should be interpreted using population-based, trimester-specific reference ranges for TSH and assay method- and trimester-specific reference ranges for serum free T<sub>4</sub>. TSH goals should target the lower half of the trimester-specific reference range (or &lt;2.5 milliunits/L when trimester-specific targets are unavailable). Patients with or at risk for hypothyroidism should undergo TSH evaluation every 4 weeks until midgestation and at least once near 30 weeks' gestation; reassess TSH 2 to 4 weeks after initiation of therapy or dosage adjustment. In patients who were initiated on levothyroxine during pregnancy, the necessity of continuing treatment postpartum should be evaluated; some patients will not require continued therapy. TSH should be measured 6 weeks after dosage adjustment or discontinuation (ATA [Alexander 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postpartum thyroiditis: </i>Monitor TSH in ~4 to 8 weeks (or if new symptoms develop) following resolution of the thyrotoxic phase of PPT to screen for hypothyroid phase. In patients receiving treatment with levothyroxine during the hypothyroid phase, monitor TSH every 6 to 8 weeks and adjust the levothyroxine dose accordingly (ATA [Alexander 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary or tertiary (central) hypothyroidism: </i>Monitor response to treatment with measurement of FT<sub>4</sub> concentrations; goal of treatment is to maintain FT<sub>4</sub> concentrations in upper half of the reference range (or slightly higher than mid-normal) (ATA [Jonklaas 2014]; Ross 2022a). TSH levels should <b>not </b>be used to monitor response to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Subclinical hypothyroidism</i>
<i>:</i> Monitor TSH every 6 weeks and adjust the dose until the TSH level is within the goal range. Once TSH levels are at goal, may recheck levels annually if they remain within the goal range; if the levothyroxine dose is adjusted or if the formulation is changed, resume monitoring TSH every 6 weeks (ATA/AACE [Garber 2012]; ETA [Pearce 2013]; Ross 2022d).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Myxedema coma:</i> Monitor thyroid function tests (FT<sub>4</sub> or T<sub>4</sub>, T<sub>3</sub>) every 1 to 2 days; serial assessment of TSH trends may also be considered to determine trend towards improvement. Monitor clinical response (eg, mental status, temperature, respiratory function, cardiovascular status, electrolytes [eg, serum sodium]) to ensure adequate parenteral thyroid hormone replacement; monitor also for safety with parenteral therapy (eg, tachycardia, arrhythmia, myocardial infarction) (ATA [Jonklaas 2014]).</p></div>
<div class="block rer drugH1Div" id="F188331"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">T<sub>4</sub> (thyroxine) serum concentrations: Adults: ~4 to 12 mcg/dL (SI: 51 to 154 nmol/L). <b>Note:</b> Normal range in pregnancy: ~5.5 to 16 mcg/dL (SI: ~71 to 206 nmol/L)</p>
<p style="text-indent:-2em;margin-left:2em;">T<sub>4</sub> free (free thyroxine; free T<sub>4</sub>) serum concentrations: Adults: 0.7 to 1.8 ng/dL (SI: 9 to 23 pmol/L). A target range in the mid to upper half of the reference range has been suggested in patients with central hypothyroidism (ES [Fleseriu 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">T<sub>3</sub> total (triiodothyronine; total T<sub>3</sub>) serum concentrations: Adults: 80 to 230 ng/dL (SI: 1.2 to 3.5 nmol/L)</p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid-stimulating hormone (TSH) serum concentrations: Adults: Varies by laboratory and assay used; refer to laboratory provided reference range. If an upper and lower limit of normal for a third generation TSH assay is not available, a reference range of 0.45 to 4.12 milliunits/L should be considered (ATA/AACE [Garber 2012]). A higher target range of 4 to 6 milliunits/L has been suggested in patients &gt;70 years of age (ATA [Jonklaas 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Subclinical hypothyroidism (elevated TSH; free T<sub>4</sub> within normal range):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (TSH ≥10 milliunits/L): These patients are at increased risk for heart failure and cardiovascular mortality and should be considered for treatment with L-thyroxine (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate (TSH 4 to 10 milliunits/L): Decision for when to treat should be tailored to individual patient based on age, symptoms, and cardiovascular risk (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p></div>
<div class="block pha drugH1Div" id="F188317"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Levothyroxine (T<sub>4</sub>) is a synthetic form of thyroxine, an endogenous hormone secreted by the thyroid gland. T<sub>4</sub> is converted to its active metabolite, L-triiodothyronine (T<sub>3</sub>). Thyroid hormones (T<sub>4</sub> and T<sub>3</sub>) then bind to thyroid receptor proteins in the cell nucleus and exert metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate</p></div>
<div class="block phk drugH1Div" id="F188336"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 3 to 5 days; peak therapeutic effect may require 4 to 6 weeks; IV: Within 6 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Erratic (40% to 80% [per manufacturer]); reported bioavailability in fasting state is 79% to 81% (Dickerson 2010; Fish 1987). Absorption may be decreased by age and specific foods and drugs.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to triiodothyronine (T<sub>3</sub>; active); ~80% thyroxine (T<sub>4</sub>) deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Euthyroid: 6 to 7 days; Hypothyroid: 9 to 10 days; Hyperthyroid: 3 to 4 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (major route of elimination; decreases with age); feces (~20%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F188344"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eferox | Eltroxin | Synthroid | Thyronorm</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Fada levotiroxina | Juno | L t | Levotiroxina | Levotiroxina fabra | Levotiroxina Glaxosmithkline | Levotiroxina northia | Synthroid | T4 montpellier</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | L thyroxin | L thyroxin henning | L-thyroxin henning | Levothyroxin stada | Syntroxine | Thyrex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Eutroxsig | Levoxine | Oroxine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Euthycin | Leroxin | Leroxy | Oroxin | Synroid | Thormon | Thynor | Thyrin | Thyrolar | Thyronor | Thyrox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elthyrone | Euthyrox | L thyroxine | Thyrax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Berlthyrox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Accu thyrox | Euthyrox | L thyroxin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Levoid | Levotiroxina sodica | Puran t4 | Synthroid | Tetroid | Tiroidin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Eltroxin lf | Euthyrox | Levothyroxin KSA | Tirosint</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Levothyrox</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Esaldox | Eutirox | Levo-tiroxina | Levotiroxina sodica | Synthroid | T4 | Thyrofix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Fu jia suo | Jia heng | Letrox | Thyroxine | You xian | Ze ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Eutirox | Levotiroxina | Levotiroxina Sodic | Levotiroxina sodica | Synthroid | Tirogal | Tiroxin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Althyxin | Eltroxin | Euthyrox | L thyroxin | L thyroxine | Letrox | Levothyroxine aristo | Levothyroxine Teva | Syntroxine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eferox | Euthyrox | Eutirox | L thyrox | L thyroxin | L thyroxin aventis | L thyroxin beta | L thyroxin henning | L thyroxin na abz | L thyroxin na ratiopharm | L-Thyrox hexal | L-thyroxin 1a pharma | L-Thyroxin Aristo | L-thyroxin beta | L-thyroxin henning | L-thyroxin ratiopharm | L-thyroxin sandoz | L-thyroxin winthrop | L-Thyroxin-Na-CT | Levothyroxin | Lixin | Thevier | Tirosint</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bagotirox | Eutirox | Eutiroxin | L t | Levoid | Levotiroxina | Levoxyl | Sintrocid | Synox | Synthroid | Tigofar | Tiroxmen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Davirox | Eltroxin | Eutirox | Levotiroxina | Tiroxin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eferox | Eltroxin | Euthyrox | L thyrox | L thyroxin | L-thyroxin bc | Thyroxin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | T4 Thyro | Thyroxin | Thyroxine | Tyraxin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dexnon | Eutirox | Levothroid | Levotiroxina aristo | Levotiroxina sanofi | Levotiroxina sodica teva | Thyrax</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Thyrofix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Medithyrox | Tefor | Thyroxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | L thyroxin henning | L-thyroxine roche | Levothyrox | Levothyroxine | Levothyroxine Biogaran | Tcaps | Thyrofix | Thyroxine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Evotrox | Levothyrox | Levothyroxin Almus | Levothyroxine | Thyroxine | Thyroxine sodium | Thyroxine sodium kent pharm</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Accu thyrox | Eltroxin | Euthyrox | L thyroxin | Levothyroxine | Medithyrox | T4 | Thyro 4 | Thyrohormone | Tirosint</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Levothyroxine | Thyroxinal | Thyroxine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Letrox | Tyraq</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | L thyroxin | Letrox | Syntroxine | Thyrax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Thyrax duo | Thyroxine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Levothyroxine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">2 crine | Eltibio | Eltroxin | Euthyroid | Euthyrox | Lethyrox | Novoroid | Roxin | Sun thyroid | Synox | Thiarx | Thryza | Thylomat | Thyobuild | Thyroace | Thyrobest | Thyrobuild | Thyrocare | Thyrocip | Thyrocloud | Thyrocut | Thyroday | Thyroff | Thyrofit | Thyronic | Thyronil | Thyronorm | Thyropax | Thyropil | Thyroquik | Thyrorich | Thyrorite | Thyrosig | Thyrosurz | Thyrotas | Thyroup | Thyroweek | Thyrox | Thyrozrak | Uthyrox</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Thyroxin-Natrium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eutirox | Levotiroxina aristo | Levotiroxina teva | Syntroxine | Tiche | Tifactor | Tirosint</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Thyroxin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Thyradin s</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Roxine | Synthroid | Telithro | Thyroberg | Thyrox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levosin | Synthyroid | Synthyroxine | Tetronine | Thyroxine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eferox | Eltroxin | Euthyrox | Letrox | Synthroid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Berlthyrox | Eltroxin | Euthyrox | L thyroxine | Letrox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | L thyrox | L thyroxin | L thyroxin berlin Chemie | L thyroxin henning | L-thyroxin berlin-chemie | Levothyroxine sodium berlin chemie</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Elthyrone | Euthyrox | L thyroxine | Thyrax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | L thyrox | L thyroxin | L thyroxin na ratiopharm | L-thyroxin henning</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">L-thyroxine roche | Levothyrox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abutiroi | Amet | Cynocuatro | Eutirox | Gentexin | Karet | Levhexal | Levotiroxin | Levotiroxina | Levotiroxina gi me | Levotiroxina iqfa | Levotiroxina kendrick | Levotiroxina sodica | Noralcodex | Sintrocid | Synthroid | Thevier | Tiroidine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Oroxine | Thyrosit | Thyroxine sodium</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Levothyroxine | Vievothroxine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Levothyroxine Christiaens | Levothyroxinenatrium aristo | Levothyroxinenatrium Teva | Thyrax | Thyrofix | Tirosint</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Berlthyrox | Eltroxin | L thyrox | L thyroxin henning | L thyroxin na ratiopharm | L-Thyrox hexal | L-thyroxin campus | L-thyroxin henning | L-thyroxin unimedic | Levaxin | Levothroid | Thyroxin-Natrium | Tirosint</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Levothyroxine | Synthroid | Tirosint</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Boncheck | Dobesium | Eutilevo | Eutirox | Eutroid-l | Levotiroxina | Levotiroxina sodica | Levotiroy | Synthroid | T4 bago | Thyromac | Tyroxcaf</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Eurolev | Euthyrox | Levothyroxine Pacific | Thydin | Thyrax | Thyrohex | Zaliana</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Rox | Thyro | Thyronorm | Thyrox | Thyroxin | Thyroxine | Thyroxinil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Althyxin | Eferox | Eltroxin | Euthyrox | Euthyrox n | L thyroxin | Letrox | Levoroxin | Vobenol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ermeza | Esi lederle levo-t | Levotabs | Levothroid | Levothyroxine | Levoxyl | Synthroid | Thyquidity | Unithroid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eutirox | L thyroxin henning | Letequatro | Letter | Levotiroxina sodica | Thyrax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Levotiroxina | Levotiroxina sodica lch | T4 | T4 bago | Tirenorm</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Eferox | Eltroxin | Euthyrox | Levotiron</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Accu thyrox | Euthyrox | Levotiroxina teva | Thyro 4</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bagothyrox | Euthyrox | L thyroxin | L thyroxin akri | L thyroxine | L-thyrok | L-thyroxin berlin-chemie | L-thyroxin hexal | L-thyroxine akri | L-Thyroxine farmak | Levothyroxine | Thyro 4</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Levaxin | Levotyroxin nycomed</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Oroxine | Thyrosit</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | L thyroxin | Levaxin | Thyroxin NA | Vobenol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | L thyroxin | L thyroxine | Tirosint</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Levotrix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">El Thyro | Eltroxin | Euthyrox | Patroxin | Pondtroxin | T 4 k p | Thyrosit | Thyroxine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Berlthyrox | L-thyroxine roche | Levothyrox | Thyro 4 | Thyrofix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Levotiron | Tefor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bagothyrox | Euthyrox | L thyroxin | L-thyrox euro | Thyro 4</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Levotiroxina | Narval | Tecuatro | Tirox</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Euthyrox | Eutirox | Levotiroxina | Levotiroxina sodica | Noralcodex | Puran t4 | Testam | Thyrax | Thyrin | Thyrona | Tigofar | Tiroxin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin | Euthyrox | Synthroid</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Eltroxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19686084">
<a name="19686084"></a>Akashi YJ, Nef HM, Möllmann H, Ueyama T. Stress cardiomyopathy. <i>Annu Rev Med</i>. 2010;61:271-286. doi:10.1146/annurev.med.041908.191750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/19686084/pubmed" id="19686084" target="_blank">19686084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30312169">
<a name="30312169"></a>Akın O. Morning vs. bedtime levothyroxine administration: what is the ideal choice for children?. <i>J Pediatr Endocrinol Metab</i>. 2018;31(11):1249-1255. doi:10.1515/jpem-2018-0168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/30312169/pubmed" id="30312169" target="_blank">30312169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum [published correction appears in <i>Thyroid. </i>2017;27(9):1212]. <i>Thyroid</i>. 2017;27(3):315-389. doi:10.1089/thy.2016.0457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16740880">
<a name="16740880"></a>American Academy of Pediatrics (AAP), Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of newborn screening and therapy for congenital hypothyroidism. <i>Pediatrics</i>. 2006;117(6):2290-2303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/16740880/pubmed" id="16740880" target="_blank">16740880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologists (ACOG). Thyroid disease in pregnancy: ACOG practice bulletin, no. 223. <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33088790">
<a name="33088790"></a>Andersen SL, Andersen S. Turning to thyroid disease in pregnant women. <i>Eur Thyroid J</i>. 2020;9(5):225-233. doi:10.1159/000506228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/33088790/pubmed" id="33088790" target="_blank">33088790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29632604">
<a name="29632604"></a>Balsa AM, Ferreira AR, Alves M, Guimarães J. Takotsubo cardiomyopathy associated with levothyroxine over-replacement. <i>Eur Endocrinol</i>. 2017;13(1):30-32. doi:10.17925/EE.2017.13.01.30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/29632604/pubmed" id="29632604" target="_blank">29632604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31350727">
<a name="31350727"></a>Bauer AJ, Wassner AJ. Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism. <i>Endocrine</i>. 2019;66(1):51-62. doi:10.1007/s12020-019-02024-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/31350727/pubmed" id="31350727" target="_blank">31350727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33639909">
<a name="33639909"></a>Bein M, Yu OHY, Grandi SM, Frati FYE, Kandil I, Filion KB. Levothyroxine and the risk of adverse pregnancy outcomes in women with subclinical hypothyroidism: a systematic review and meta-analysis. <i>BMC Endocr Disord</i>. 2021;21(1):34. doi:10.1186/s12902-021-00699-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/33639909/pubmed" id="33639909" target="_blank">33639909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11134131">
<a name="11134131"></a>Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. <i>J Clin Endocrinol Metab</i>. 2000;85(12):4701-4705. doi:10.1210/jcem.85.12.7085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11134131/pubmed" id="11134131" target="_blank">11134131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burman.1">
<a name="Burman.1"></a>Burman KD. Postpartum thyroiditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081673">
<a name="31081673"></a>Cappola AR, Desai AS, Medici M, et al. Thyroid and cardiovascular disease research agenda for enhancing knowledge, prevention, and treatment. <i>Circulation</i>. 2019:10.1161/CIRCULATIONAHA.118.036859. doi:10.1161/CIRCULATIONAHA.118.036859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/31081673/pubmed" id="31081673" target="_blank">31081673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23264396">
<a name="23264396"></a>Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.<i> J Clin Endocrinol Metab</i>. 2013;98(2):610-617. doi:10.1210/jc.2012-3125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23264396/pubmed" id="23264396" target="_blank">23264396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23312689">
<a name="23312689"></a>Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. <i>J Pediatr</i>. 2013;162(6):1264-1269.e12692. doi:10.1016/j.jpeds.2012.11.070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23312689/pubmed" id="23312689" target="_blank">23312689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3510598">
<a name="3510598"></a>Coindre JM, David JP, Rivière L, et al. Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. <i>Arch Intern Med</i>. 1986;146(1):48-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/3510598/pubmed" id="3510598" target="_blank">3510598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytomel.1">
<a name="Cytomel.1"></a>Cytomel (liothyronine) [prescribing information]. New York, NY: Pfizer Inc; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16198662">
<a name="16198662"></a>de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. <i>Clin Pharmacol Ther.</i> 2005;78(4):433-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/16198662/pubmed" id="16198662" target="_blank">16198662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21139130">
<a name="21139130"></a>Dickerson RN, Maish GO 3rd, Minard G, Brown RO. Clinical relevancy of the levothyroxine-continuous enteral nutrition interaction. <i>Nutr Clin Pract</i>. 2010;25(6):646-652. doi: 10.1177/0884533610385701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/21139130/pubmed" id="21139130" target="_blank">21139130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eltroxin.1">
<a name="Eltroxin.1"></a>Eltroxin (levothyroxine) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ermeza.1">
<a name="Ermeza.1"></a>Ermeza (levothyroxine sodium) [prescribing information]. Morgantown, WV: Mylan Specialty LP; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Euthyrox.1">
<a name="Euthyrox.1"></a>Euthyrox (levothyroxine sodium) [prescribing information]. Honey Brook, PA: Provell Pharmaceuticals LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Euthyrox.2">
<a name="Euthyrox.2"></a>Euthyrox (levothyroxine sodium) [product monograph]. Mississauga, Ontario, Canada: EMD Inc Canada; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Farwell.1">
<a name="Farwell.1"></a>Farwell AP. Sporadic Painless, Painful Subacute and Acute Infectious Thyroiditis. In: Braverman LE, Cooper DS. <i>Werner &amp; Ingbar's The Thyroid: A Fundamental and Clinical Text</i>. 10th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2013:418-422.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30285179">
<a name="30285179"></a>Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. <i>JAMA</i>. 2018;320(13):1349-1359. doi:10.1001/jama.2018.13770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/30285179/pubmed" id="30285179" target="_blank">30285179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3821822">
<a name="3821822"></a>Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. <i>N Engl J Med</i>. 1987;316(13):764-770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/3821822/pubmed" id="3821822" target="_blank">3821822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25900731">
<a name="25900731"></a>Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i>. 2015;25(7):716-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25900731/pubmed" id="25900731" target="_blank">25900731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23246686">
<a name="23246686"></a>Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association taskforce on hypothyroidism in adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [published correction appears in <i>Endocr Pract. </i>2013;19(1):175]. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23246686/pubmed" id="23246686" target="_blank">23246686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27167915">
<a name="27167915"></a>Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update. <i>Endocr Pract</i>. 2016;22(5):622-639. doi:10.4158/EP161208.GL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/27167915/pubmed" id="27167915" target="_blank">27167915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32975922">
<a name="32975922"></a>Gietka-Czernel M, Glinicki P. Subclinical hypothyroidism in pregnancy: controversies on diagnosis and treatment. <i>Pol Arch Intern Med</i>. 2021;131(3):266-275. doi:10.20452/pamw.15626<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/32975922/pubmed" id="32975922" target="_blank">32975922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23981741">
<a name="23981741"></a>Gupta VD. Stability of levothyroxine sodium injection in polypropylene syringes. <i>Int J Pharm Compound.</i> 2000;4(6):482-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23981741/pubmed" id="23981741" target="_blank">23981741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26462967">
<a name="26462967"></a>Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi:10.1089/thy.2015.0020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/26462967/pubmed" id="26462967" target="_blank">26462967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31623668">
<a name="31623668"></a>Hlaihel AF, Al-Khairalla MZH. Levothyroxine-induced liver injury followed by complete recovery upon cessation of the drug: a case report. <i>J Med Case Rep</i>. 2019;13(1):311. doi:10.1186/s13256-019-2244-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/31623668/pubmed" id="31623668" target="_blank">31623668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23539727">
<a name="23539727"></a>Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. <i>J Clin Endocrinol Metab</i>. 2013;98(5):1982-1990. doi:10.1210/jc.2012-4107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23539727/pubmed" id="23539727" target="_blank">23539727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266247">
<a name="25266247"></a>Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. <i>Thyroid</i>. 2014;24(12):1670-1751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25266247/pubmed" id="25266247" target="_blank">25266247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771481">
<a name="12771481"></a>Kaur S, Bhalla M, Thami GP. Subacute lichenoid eruption due to L-thyroxine overdosage. <i>Dermatology</i>. 2003;206(4):346-347. doi:10.1159/000069952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12771481/pubmed" id="12771481" target="_blank">12771481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13752096">
<a name="13752096"></a>Keating FR Jr, Parkin TW, Selby JB, Dickinson LS. Treatment of heart disease associated with myxedema. <i>Prog Cardiovasc Dis</i>. 1961;3:364-381. doi:10.1016/s0033-0620(61)90004-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/13752096/pubmed" id="13752096" target="_blank">13752096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17923583">
<a name="17923583"></a>Klein I, Danzi S. Thyroid disease and the heart. <i>Circulation</i>. 2007;116(15):1725-1735. doi:10.1161/CIRCULATIONAHA.106.678326 Erratum in: <i>Circulation</i>. 2008;117(3):e18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/17923583/pubmed" id="17923583" target="_blank">17923583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25978154">
<a name="25978154"></a>Kotloff RM, Blosser S, Fulda GJ, et al; Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Donor Management Task Force. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. <i>Crit Care Med.</i> 2015;43(6):1291-1325. doi:10.1097/CCM.0000000000000958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25978154/pubmed" id="25978154" target="_blank">25978154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27275040">
<a name="27275040"></a>Kumar L. Brain death and care of the organ donor. <i>J Anaesthesiol Clin Pharmacol.</i> 2016;32(2):146-152. doi:10.4103/0970-9185.168266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/27275040/pubmed" id="27275040" target="_blank">27275040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25088372">
<a name="25088372"></a>Lee DY, Seok J, Jeong WJ, Ahn SH. Prediction of thyroid hormone supplementation after thyroid lobectomy. <i>J Surg Res.</i> 2015;193(1):273-278. doi:10.1016/j.jss.2014.07.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25088372/pubmed" id="25088372" target="_blank">25088372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24662106">
<a name="24662106"></a>Léger J, Olivieri A, Donaldson M, et al; ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE; Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. <i>Horm Res Paediatr</i>. 2014;81(2):80-103. doi:10.1159/000358198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24662106/pubmed" id="24662106" target="_blank">24662106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levolet.1">
<a name="Levolet.1"></a>Levolet (levothyroxine sodium) [prescribing information]. Allentown, PA: Genus Lifesciences Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AVIR.1">
<a name="AVIR.1"></a>Levothyroxine for injection [prescribing information]. Blainville, Quebec, Canada: AVIR Pharmaceuticals Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Levothyroxine for injection [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucadia.1">
<a name="Leucadia.1"></a>Levothyroxine sodium for injection [prescribing information]. Carlsbad, CA: Leucadia Pharmaceuticals; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FreseniusKabi.1">
<a name="FreseniusKabi.1"></a>Levothyroxine sodium for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FreseniusKabi.2">
<a name="FreseniusKabi.2"></a>Levothyroxine sodium for injection [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levoxyl.1">
<a name="Levoxyl.1"></a>Levoxyl (levothyroxine sodium) [prescribing information]. New York, NY: Pfizer; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levoxyl.2">
<a name="Levoxyl.2"></a>Levoxyl tablets (levothyroxine) [prescribing information]. New York, NY: Pfizer Inc.; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11576928">
<a name="11576928"></a>Lim VS. Thyroid function in patients with chronic renal failure. <i>Am J Kidney Dis</i>. 2001;38(4)(suppl 1):S80-S84. doi:10.1053/ajkd.2001.27410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11576928/pubmed" id="11576928" target="_blank">11576928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22511141">
<a name="22511141"></a>Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. <i>Crit Care Med</i>. 2012;40(5):1635-1644. doi:10.1097/CCM.0b013e3182416ee7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/22511141/pubmed" id="22511141" target="_blank">22511141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manzullo.1">
<a name="Manzullo.1"></a>Manzullo EF, Ross DS. Nonthyroid surgery in the patient with thyroid disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22021708">
<a name="22021708"></a>Mariani LH, Berns JS. The renal manifestations of thyroid disease. <i>J Am Soc Nephrol</i>. 2012;23(1):22-26. doi:10.1681/ASN.2010070766.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/22021708/pubmed" id="22021708" target="_blank">22021708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nakagawa.1">
<a name="Nakagawa.1"></a>Nakagawa TA. Updated pediatric donor management and dosing guidelines. Published 2008. Last accessed June 2012. http://www.natco1.org/prof_development/documents/FINALNATCOPedDonorManagementGuidelines_Jan08.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30844908">
<a name="30844908"></a>Nguyen CT, Mestman JH. Postpartum thyroiditis. <i>Clin Obstet Gynecol</i>. 2019;62(2):359-364. doi:10.1097/GRF.0000000000000430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/30844908/pubmed" id="30844908" target="_blank">30844908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26686437">
<a name="26686437"></a>Novitzky D, Mi Z, Collins JF, Cooper DK. Increased procurement of thoracic donor organs after thyroid hormone therapy. <i>Semin Thorac Cardiovasc Surg</i>. 2015;27(2):123-132. doi:10.1053/j.semtcvs.2015.06.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/26686437/pubmed" id="26686437" target="_blank">26686437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25405914">
<a name="25405914"></a>Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. <i>Transplantation</i>. 2014;98(10):1119-1127. doi:10.1097/TP.0000000000000187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25405914/pubmed" id="25405914" target="_blank">25405914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17379984">
<a name="17379984"></a>Oe K, Yamagata T, Mori K. Acute myocardial infarction following hormone replacement in hypothyroidism. <i>Int Heart J</i>. 2007;48(1):107-111. doi:10.1536/ihj.48.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/17379984/pubmed" id="17379984" target="_blank">17379984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11567699">
<a name="11567699"></a>Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. <i>Lancet.</i> 2001;358(9285):861-865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11567699/pubmed" id="11567699" target="_blank">11567699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24783053">
<a name="24783053"></a>Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. <i>Eur Thyroid J</i>. 2013;2(4):215-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24783053/pubmed" id="24783053" target="_blank">24783053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1113223">
<a name="1113223"></a>Penfold JL, Simpson DA. Premature craniosynostosis-a complication of thyroid replacement therapy. <i>J Pediatr</i>. 1975;86(3):360-363. doi:10.1016/s0022-3476(75)80963-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/1113223/pubmed" id="1113223" target="_blank">1113223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24247169">
<a name="24247169"></a>Peroni E, Vigone MC, Mora S, et al. Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. <i>Horm Res Paediatr</i>. 2014;81(1):50-54. doi:10.1159/000356047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24247169/pubmed" id="24247169" target="_blank">24247169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24789541">
<a name="24789541"></a>Pirola I, Daffini L, Gandossi E, et al. Comparison between liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube. <i>J Endocrinol Invest</i>. 2014;37(6):583-587. doi:10.1007/s40618-014-0082-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24789541/pubmed" id="24789541" target="_blank">24789541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33718252">
<a name="33718252"></a>Poppe K, Bisschop P, Fugazzola L, Minziori G, Unuane D, Weghofer A. 2021 European Thyroid Association guideline on thyroid disorders prior to and during assisted reproduction. <i>Eur Thyroid J</i>. 2021;9(6):281-295. doi:10.1159/000512790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/33718252/pubmed" id="33718252" target="_blank">33718252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Radhakrishnan.1">
<a name="Radhakrishnan.1"></a>Radhakrishnan R, Venkatasamy S, Pyarejan K, Jayachandran K. Effectiveness of bedtime levothyroxine intake as compared to morning levothyroxine intake in children. <i>Int J Contemp Pediatr</i>. 2017;4(6):1969-1974. doi:http://dx.doi.org/10.18203/2349-3291.ijcp20174155</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16087818">
<a name="16087818"></a>Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial [published correction appears in <i>Arch Intern Med</i>. 2005;165(19):2227]. <i>Arch Intern Med.</i> 2005;165(15):1714-1720. doi:10.1001/archinte.165.15.1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/16087818/pubmed" id="16087818" target="_blank">16087818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12605114">
<a name="12605114"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. <i>Transplantation.</i> 2003a;75(4):482-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12605114/pubmed" id="12605114" target="_blank">12605114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12717226">
<a name="12717226"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12717226/pubmed" id="12717226" target="_blank">12717226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Central hypothyroidism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.2">
<a name="Ross.2"></a>Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.3">
<a name="Ross.3"></a>Ross DS. Myxedema coma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.4">
<a name="Ross.4"></a>Ross DS. Subclinical hypothyroidism in nonpregnant adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2022d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.5">
<a name="Ross.5"></a>Ross DS. Treatment of primary hypothyroidism in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 29, 2022e.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18517088">
<a name="18517088"></a>Sala A, Labrador-Horrillo M, Guilarte M, Luengo O, Rueda M, Cardona V. Immediate-type hypersensitivity reaction to levothyroxine and desensitization. <i>Ann Allergy Asthma Immunol</i>. 2008;100(5):513-514. doi:10.1016/S1081-1206(10)60481-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/18517088/pubmed" id="18517088" target="_blank">18517088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17488392">
<a name="17488392"></a>Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. <i>Clin Transplant.</i> 2007;21(3):405-409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/17488392/pubmed" id="17488392" target="_blank">17488392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15483074">
<a name="15483074"></a>Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases.<i> J Clin Endocrinol Metab.</i> 2005;90(1):124-127. doi: 10.1210/jc.2004-1306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/15483074/pubmed" id="15483074" target="_blank">15483074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1391296">
<a name="1391296"></a>Schlote B, Schaaf L, Schmidt R, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. <i>Biol Psychiatry</i>. 1992;32(1):48-56. doi:10.1016/0006-3223(92)90141-l<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/1391296/pubmed" id="1391296" target="_blank">1391296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7848399">
<a name="7848399"></a>Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. <i>JAMA</i>. 1994;271(16):1245-1249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/7848399/pubmed" id="7848399" target="_blank">7848399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12461494">
<a name="12461494"></a>Selva KA, Mandel SH, Rien L, et al. Initial Treatment Dose of L-thyroxine in Congenital Hypothyroidism. <i>J Pediatr.</i> 2002;141(6):786-792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12461494/pubmed" id="12461494" target="_blank">12461494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34185829">
<a name="34185829"></a>Shakir MKM, Brooks DI, McAninch EA, et al. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. <i>J Clin Endocrinol Metab</i>. 2021;106(11):e4400-e4413. doi:10.1210/clinem/dgab478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/34185829/pubmed" id="34185829" target="_blank">34185829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22312089">
<a name="22312089"></a>Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. <i>J Clin Endocrinol Metab.</i> 2012;97(2):334-342. doi:10.1210/jc.2011-2576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/22312089/pubmed" id="22312089" target="_blank">22312089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28402245">
<a name="28402245"></a>Stott DJ, Rodondi N, Kearney PM, et al; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. <i>N Engl J Med</i>. 2017;376(26):2534-2544. doi:10.1056/NEJMoa1603825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/28402245/pubmed" id="28402245" target="_blank">28402245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22479016">
<a name="22479016"></a>Strong DK, Decarie D, Ensom MH. Stability of levothyroxine in sodium chloride for IV administration. <i>Can J Hosp Pharm</i>. 2010;63(6):437-443. doi:10.4212/cjhp.v63i6.963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/22479016/pubmed" id="22479016" target="_blank">22479016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Synthroid.1">
<a name="Synthroid.1"></a>Synthroid (levothyroxine) tablets [prescribing information]. North Chicago, IL: AbbVie Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Synthroid.2">
<a name="Synthroid.2"></a>Synthroid (levothyroxine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thyquidity.1">
<a name="Thyquidity.1"></a>Thyquidity (levothyroxine) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thyrolar.1">
<a name="Thyrolar.1"></a>Thyrolar (liotrix tablets) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; January 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tirocap.1">
<a name="Tirocap.1"></a>Tirocap (levothyroxine) [product monograph]. Newmarket, Ontario, Canada: Progress Therapeutics; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tirosint.1">
<a name="Tirosint.1"></a>Tirosint (levothyroxine) [prescribing information]. Parsippany, NJ: IBSA Pharma Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tirosint-Sol.1">
<a name="Tirosint-Sol.1"></a>Tirosint-SOL (levothyroxine) [prescribing information]. Parsippany, NJ: IBSA Pharma Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31598570">
<a name="31598570"></a>Toloza FJK, Singh Ospina NM, Rodriguez-Gutierrez R, O'Keeffe DT, Brito JP, Montori VM, Maraka S. Practice variation in the care of subclinical hypothyroidism during pregnancy: a national survey of physicians in the United States. <i>J Endocr Soc</i>. 2019;3(10):1892-1906. doi:10.1210/js.2019-00196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/31598570/pubmed" id="31598570" target="_blank">31598570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tuttle.1">
<a name="Tuttle.1"></a>Tuttle RM. Differentiated thyroid cancer: Overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Unithroid.1">
<a name="Unithroid.1"></a>Unithroid (levothyroxine sodium) [prescribing information]. Bridgewater, NJ: Amneal Specialty; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33272083">
<a name="33272083"></a>van Trotsenburg P, Stoupa A, Léger J, et al. Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. <i>Thyroid</i>. 2021;31(3):387-419. doi:10.1089/thy.2020.0333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/33272083/pubmed" id="33272083" target="_blank">33272083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12030913">
<a name="12030913"></a>van Wassenaer AG, Stulp MR, Valianpour F, et al, The quantity of thyroid hormone in human milk Is too low to influence plasma thyroid hormone levels in the very preterm infant. <i>Clin Endocrinol (Oxf)</i>. 2002;56(5):621-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12030913/pubmed" id="12030913" target="_blank">12030913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wassner.1">
<a name="Wassner.1"></a>Wassner AJ, Smith JR. Hypothyroidism. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap 581.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28100579">
<a name="28100579"></a>Yu MG, Flores KM, Isip-Tan IT. Acute mania after levothyroxine replacement for hypothyroid-induced heart block. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218819. doi:10.1136/bcr-2016-218819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/28100579/pubmed" id="28100579" target="_blank">28100579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29184434">
<a name="29184434"></a>Zeitjian V, Moazez C, Saririan M, August DL, Roy R. Manifestation of non-ST elevation myocardial infarction due to hyperthyroidism in an anomalous right coronary artery. <i>Int J Gen Med</i>. 2017;10:409-413. doi:10.2147/IJGM.S146921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/29184434/pubmed" id="29184434" target="_blank">29184434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20547262">
<a name="20547262"></a>Zeitler P, Solberg P, Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Food and levothyroxine administration in infants and children. <i>J Pediatr.</i> 2010;157(1):13-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/20547262/pubmed" id="20547262" target="_blank">20547262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15640648">
<a name="15640648"></a>Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. <i>Crit Care Med.</i> 2004;32(11):2318-2322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/15640648/pubmed" id="15640648" target="_blank">15640648</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9557 Version 712.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
